Stock AnalizRLX Technology Inc. RLX
Medicinal Chemicals and Botanical Products · IPO 2021 · data as of November 13, 2026
RLX Technology Inc. (RLX) is a healthcare company listed in the US with a market value of about $1.9B. In the twelve months to June 30, 2026 it had revenue of $675M and net income of $148M, a net margin of 21.9%.
Its overall Stock Analiz score is 3.2 out of 5 (average). The strongest part is financial health (5/5); the weakest is track record (1/5).
Key numbers: a P/E of 14.2, a price to free cash flow of 30.5, 5-year revenue growth of -1% a year, a 5-year average ROIC of 3%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 369% above the current price.
Score: 3.2 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- Price below intrinsic value (DCF, moderate assumptions)
- Revenue growth above 10% last year
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
- Profitable 5 years in a row
- More cash than debt, or low debt to equity
Checks not passed
- P/FCF below 20
- PEG below 1.5
- 3-year revenue growth above 10% a year
- Profit margin improving
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
- 5-year average ROIC above 12%
- ROE above 15%
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $675M | $566M | $377M | $223M | $773M | $1.3B | $585M |
| Net income | $148M | $132M | $76M | $75M | $209M | $318M | -$20M |
| Free cash flow | $62M | $141M | $116M | $24M | $65M | $262M | $395M |
| EPS (diluted) | $0.12 | $0.11 | $0.06 | $0.06 | $0.17 | $0.26 | $-0.02 |
| Net margin | 21.9% | 23.3% | 20.1% | 33.7% | 27.0% | 23.8% | -3.4% |
| ROIC | — | 1.8% | -0.6% | -2.9% | 5.3% | 12.1% | 0.4% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
What is RLX Technology’s P/E ratio?
About 14.2, based on the last twelve months of diluted earnings per share (forward P/E about 9.5).
Is RLX Technology stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 369% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does RLX Technology pay a dividend?
Yes. The dividend yield is about 6.49%, and it has paid dividends for 3 years in our data.
Is RLX Technology a good stock to buy?
We do not give buy or sell advice. RLX Technology scores 3.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.